Pharmacogenomics Journal

Papers
(The TQCC of Pharmacogenomics Journal is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study87
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data49
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform36
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study32
STRIPE partners in precision medicine series: provider perspective24
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study23
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone19
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration13
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care13
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients13
Using ChatGPT to predict the future of personalized medicine13
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder12
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?10
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population10
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients10
STRIPE partners in precision medicine series: Patient perspective10
APF2: an improved ensemble method for pharmacogenomic variant effect prediction9
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing9
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer9
CYP2C19 point-of-care testing: where are we now and where should we go?8
Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs8
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis7
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress7
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population7
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications6
Potential of pharmacogenetics in treatment of chronic inflammatory diseases – a danish report overview from 2000 – 20246
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine6
Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients6
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects6
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance6
Genetic markers of early response to lurasidone in acute schizophrenia6
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)6
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study5
A blockchain-based framework to support pharmacogenetic data sharing5
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics5
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer5
Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population5
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci5
Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review5
Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study5
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy5
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients5
An innovative model for pharmacogenomics critical results identification and intervention5
0.074023008346558